NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse

Cardiovascular Research

Volumn 85, Issue 1, 2010, Pages 204-213

  Kauffenstein, Gilles ^a   Drouin, Annick ^b   Thorin Trescases, Nathalie ^b   Bachelard, Hélne ^a   Robaye, Bernard ^c   D'Orléans Juste, Pedro ^d   Marceau, François ^a   Thorin, Éric ^b   Sévigny, Jean ^a  

^a LAVAL UNIVERSITY   (Canada)

^b MONTREAL HEART INSTITUTE   (Canada)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

CD39; Myogenic tone; NTPDase1; P2Y receptor; Smooth muscle cell; UDP; UTP; Vasoconstriction

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; GUANOSINE DIPHOSPHATE; PURINERGIC P2 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y13 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; PYRIMIDINE NUCLEOTIDE; URIDINE DIPHOSPHATE; URIDINE TRIPHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CONTROLLED STUDY; ENZYME ACTIVITY; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 72049103706     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp265     Document Type: Article

References (50)

1. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006;58:58-86.
2. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal 2008;4:1-20.
3. Lazarowski ER, Boucher RC, Harden TK. Mechanisms of release of nucleotides and integration of their action as P2X-and P2Y-receptor activating molecules. Mol Pharmacol 2003;64:785-795.
4. Vonend O, Stegbauer J, Sojka J, Habbel S, Quack I, Robaye B et al. Noradrenaline and extracellular nucleotide cotransmission involves activation of vasoconstrictive P2X(1,3)-and P2Y6-like receptors in mouse perfused kidney. Br J Pharmacol 2005; 145:66-74.
5. North RA Molecular physiology of P2X receptors. Physiol Rev 2002;82: 1013-1067.
6. von Kugelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 2006;110:415-432.
7. Yamamoto K, Sokabe T, Matsumoto T, Yoshimura K, Shibata M, Ohura N et al. Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat Med 2006;12:133-137.
8. Harrington LS, Evans RJ, Wray J, Norling L, Swales KE, Vial C et al. Purinergic 2X1 receptors mediate endothelial dependent vasodilation to ATP. Mol Pharmacol 2007;72:1132-1136.
9. Gitterman DP, Evans RJ. Nerve evoked P2X receptor contractions of rat mesenteric arteries; dependence on vessel size and lack of role of L-type calcium channels and calcium induced calcium release. Br J Pharmacol 2001;132: 1201-1208.
10. Malmsjo M, Adner M, Harden TK, Pendergast W, Edvinsson L, Erlinge D. The stable pyrimidines UDPbetaS and UTPgammaS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery. Br J Pharmacol 2000;131:51-56.
11. von Kugelgen I, Haussinger D, Starke K. Evidence for a vasoconstriction-mediating receptor for UTP, distinct from the P2 purinoceptor, in rabbit ear artery. Naunyn Schmiedebergs Arch Pharmacol 1987;336:556-560.
12. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000;362:299-309.
13. Sévigny J, Sundberg C, Braun N, Guckelberger O, Csizmadia E, Qawi I et al. Differential catalytic properties and vascular topography of murine nucleoside tri-phosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 2002;99:2801-2809.
14. Marcus AJ, Safier LB, Hajjar KA, Ullman HL, Islam N, Broekman MJ et al. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thrombor-egulation by endothelial cells. J Clin Invest 1991;88:1690-1696.
15. Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, Beaudoin AR et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 1996;271:33116-33122.
16. Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, Ramasamy R et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 2002;109:1031-1040.
17. Enjyoji K, Sévigny J, Lin Y, Frenette PS, Christie PD, Esch JS II et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999;5:1010-1017.
18. Guckelberger O, Sun XF, Sévigny J, Imai M, Kaczmarek E, Enjyoji K et al. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb Haemost 2004;91:576-586.
19. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003;198:783-796.
20. Martin-Satué M, Lavoie EG, Pelletier J, Fausther M, Csizmadia E, Guckelberger O et al. Localization of plasma membrane bound NTPDases in the murine reproductive tract. Histochem Cell Biol 2009;131:615-628.
21. Braun N, Sévigny J, Robson SC, Enjyoji K, Guckelberger O, Hammer K et al. Assignment of ecto-nucleoside triphosphate diphosphohydrolase-1/cd39 expression to microglia and vasculature of the brain. Eur J Neurosci 2000;12:4357-4366.
22. Moon SK, Thompson LJ, Madamanchi N, Ballinger S, Papaconstantinou J, Horaist C et al. Aging, oxidative responses, and proliferative capacity in cultured mouse aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 2001;280:H2779-H2788.
23. Kukulski F, Levesque SA, Lavoie EG, Lecka J, Bigonnesse F, Knowles AF et al. Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal 2005;1:193-204.
24. Heine P, Braun N, Heilbronn A, Zimmermann H. Functional characterization of rat ecto-ATPase and ecto-ATP diphosphohydrolase after heterologous expression in CHO cells. Eur J Biochem 1999;262:102-107.
25. El-Tayeb A, Qi A, Muller CE. Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem 2006;49:7076-7087.
26. Guns PJ, Van Assche T, Fransen P, Robaye B, Boeynaems JM, Bult H. Endothelium-dependent relaxation evoked by ATP and UTP in the aorta of P2Y2-deficient mice. Br J Pharmacol 2006;147:569-574.
27. Bar I, Guns PJ, Metallo J, Cammarata D, Wilkin F, Boeynams JM et al. Knockout mice reveal a role for P2Y6 receptor in macrophages, endothelial cells, and vascular smooth muscle cells. Mol Pharmacol 2008;74:777-784.
28. Henrion D. Pressure and flow-dependent tone in resistance arteries. Role of myogenic tone. Arch Mal Coeur Vaiss 2005;98:913-921.
29. Gordon EL, Pearson JD, Dickinson ES, Moreau D, Slakey LL. The hydrolysis of extracellular adenine nucleotides by arterial smooth muscle cells. Regulation of adenosine production at the cell surface. J Biol Chem 1989;264:18986-18995.
30. Vial C, Evans RJ. P2X(1) receptor-deficient mice establish the native P2X receptor and a P2Y6-like receptor in arteries. Mol Pharmacol 2002;62:1438-1445.
31. Erlinge D, Hou M, Webb TE, Barnard EA, Moller S. Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR. Biochem Biophys Res Commun 1998;248:864-870.
32. Kumari R, Goh G, Ng LL, Boarder MR. ATP and UTP responses of cultured rat aortic smooth muscle cells revisited: dominance of P2Y2 receptors. Br J Pharmacol 2003;140:1169-1176.
33. Yu N, Erb L, Shivaji R, Weisman GA, Seye CI. Binding of the P2Y2 nucleotide receptor to filamin A regulates migration of vascular smooth muscle cells. Circ Res 2008;102:581-588.
34. Communi D, Parmentier M, Boeynaems JM. Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun 1996;222:303-308. (Pubitemid 26335011)
35. Hartley SA, Kato K, Salter KJ, Kozlowski RZ. Functional evidence for a novel suramin-insensitive pyrimidine receptor in rat small pulmonary arteries. Circ Res 1998;83:940-946.
36. Schaefer U, Machida T, Broekman MJ, Marcus AJ, Levi R. Targeted deletion of ectonucleoside triphosphate diphosphohydrolase 1/CD39 leads to desensitiza-tion of pre-and postsynaptic purinergic P2 receptors. J Pharmacol Exp Ther 2007;322:1269-1277.
37. Mizumoto N, Kumamoto T, Robson SC, Sevigny J, Matsue H, Enjyoji K et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med 2002;8:358-365.
38. Goepfert C, Sundberg C, Sévigny J, Enjyoji K, Hoshi T, Csizmadia E et al. Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 2001;104: 3109-3115.
39. Robson SC, Sévigny J, Zimmermann H. The E-NTPDase family of ectonucleoti-dases: Structure function relationships and pathophysiological significance. Puriner-gic Signal 2006;2:409-430.
40. Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG et al. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res 2000;87:60-65.
41. Bolz SS, Vogel L, Sollinger D, Derwand R, Boer C, Pitson SM et al. Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase. Circulation 2003;108:342-347.
42. Lazarowski ER, Homolya L, Boucher RC, Harden TK. Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. J Biol Chem 1997;272:24348-24354.
43. Dubyak GR, el-Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 1993;265:C577-C606.
44. Clark MG, Richards SM, Hettiarachchi M, Ye JM, Appleby GJ, Rattigan S et al. Release of purine and pyrimidine nucleosides and their catabolites from the perfused rat hindlimb in response to noradrenaline, vasopressin, angiotensin II and sciatic-nerve stimulation. Biochem J 1990;266:765-770.
45. Nishida M, Sato Y, Uemura A, Narita Y, Tozaki-Saitoh H, Nakaya M et al. P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J 2008;27:3104-3115.
46. Koltsova SV, Maximov GV, Kotelevtsev SV, Lavoie JL, Tremblay J, Grygorczyk R et al. Myogenic tone in mouse mesenteric arteries: evidence for P2Y receptor-mediated, Na(+), K (+), 2Cl (2) cotransport-dependent signaling. Purinergic Signal 2009;5:343-349.
47. Robson SC, Kaczmarek E, Siegel JB, Candinas D, Koziak K, Millan M et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185:153-163.
48. Ho WS, Randall MD. Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol 2007;150:641-651.
49. Jackson EK, Dubinion JH, Mi Z. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. Clin Exp Pharmacol Physiol 2008;35:29-34.
50. Peter BF, Lidington D, Harada A, Bolz HJ, Vogel L, Heximer S et al. Role of sphingosine-1-phosphate phosphohydrolase 1 in the regulation of resistance artery tone. Circ Res 2008;103:315-324.